ATHE · Alterity Therapeutics Limited

Alterity Therapeutics announced positive written feedback from the FDA following a second Type C meeting regarding the chemistry, manufacturing, and control (CMC) elements of its ATH434 Phase 3 development program for Multiple System Atrophy (MSA). This regulatory milestone follows a first Type C meeting in March that addressed clinical pharmacology and non-clinical aspects. The FDA's endorsement of the manufacturing and testing plans supports readiness for Phase 3 initiation, with manufacturing scale-up already underway. The company remains on track for an End-of-Phase 2 meeting in mid-2026. ATH434 has previously shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial, and positive data from an open-label Phase 2 study in advanced MSA patients. MSA is a rare, rapidly progressive neurodegenerative disease with no approved disease-modifying treatments, underscoring the potential significance of ATH434. The positive FDA feedback reduces regulatory risk and paves the way for pivotal trial commencement, which is a critical value inflection point for the company.